Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | PAM | P19021 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718707 | 1.00 | CYP2C19 (0.39) | CYP2C19CYP2D6ALDH1A1HIF1APAM | |
| SCHEMBL23630231 | 0.77 | APP (0.34) | — | |
| SCHEMBL10823737 | 0.75 | — | — | |
| SCHEMBL27233271 | 0.73 | — | — | |
| SCHEMBL23630235 | 0.73 | APP (0.33) | — | |
| SCHEMBL11272382 | 0.73 | — | — | |
| SCHEMBL11449481 | 0.73 | — | — | |
| SCHEMBL27233249 | 0.70 | — | — | |
| SCHEMBL28902114 | 0.68 | CYP2C19 (0.41) | CYP2C19CYP2D6ALDH1A1HIF1APAM | |
| SCHEMBL23630237 | 0.67 | NOS1 (0.40) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552066-B2 | Modified chalcone compounds as antimitotic agents | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2029527-B1 | MODIFIED CHALCONE COMPOUNDS AS ANTIMITOTIC AGENTS | ARIZONA BIOMEDICAL RES COMMISSION (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2447248-A2 | Modified chalcone compounds as antimitotic agents | Arizona Biomedical Research Commission (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20100222380-A1 | Modified Chalcone Compounds as Antimitotic Agents | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2010-09-02 | — | — | US | disclosed |
| US-7714025-B2 | Modified chalcone compounds as antimitotic agents | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2010-05-11 | — | — | US | disclosed |
| EP-2029527-A2 | MODIFIED CHALCONE COMPOUNDS AS ANTIMITOTIC AGENTS | Arizona Biomedical Research Commission (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007133588-A2 | MODIFIED CHALCONE COMPOUNDS AS ANTIMITOTIC AGENTS | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070265317-A1 | MODIFIED CHALCONE COMPOUNDS AS ANTIMITOTIC AGENTS | ARIZONA BIOMEDICAL RESEARCH COMMISSION (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265317-A1 | MODIFIED CHALCONE COMPOUNDS AS ANTIMITOTIC AGENTS | TUBA1C, SARS1, TUBB1 | CYP2C19 2846/4885CYP2D6 1318/4885ALDH1A1 2821/4885 |
| US-20100222380-A1 | Modified Chalcone Compounds as Antimitotic Agents | TUBA1C, SARS1, TUBB1 | CYP2C19 2891/4885CYP2D6 1360/4885ALDH1A1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.